Posted by Michael Wonder on 24 Jul 2018
How the Trump Administration is browbeating big pharma on drug prices
23 July 2018 - Eric D. Hargan, the deputy secretary of health and human services, told the board of the Pharmaceutical Research and Manufacturers of America that a continuation of aggressive price increases could invite distasteful remedies.
When titans of the pharmaceutical industry met here last week at the opulent Mandarin Oriental Hotel, Trump administration officials issued a blunt warning to the chief executives on the soaring prices of their medicine.
Eric D. Hargan, the deputy secretary of health and human services, told the board of the Pharmaceutical Research and Manufacturers of America that the Trump administration strongly favoured free-market solutions.
